Abstract
[(11)C]Carfentanil (CFN) is a mu-opioid agonist used for in vivo positron emission tomography (PET) studies of mu-opioid receptors. Previously, a tissue-ratio method was validated for the quantification of CFN binding. However, since that initial validation, several other blood independent (reference-tissue) methods have become available. To evaluate these methods, CFN PET studies with arterial blood sampling were acquired in six healthy male control subjects. Specific binding estimates obtained from reference-tissue methods were compared to those obtained with a more rigorous blood input modeling technique. It was determined that both a graphical method, and a simplified reference tissue model, were more accurate than the tissue-ratio method for quantification of CFN binding.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
-
Validation Study
MeSH terms
-
Adult
-
Animals
-
Brain / diagnostic imaging
-
Brain / metabolism*
-
Carbon Radioisotopes / blood
-
Carbon Radioisotopes / pharmacokinetics
-
Computer Simulation
-
Cytochromes
-
Electron Transport Complex IV
-
Fentanyl / analogs & derivatives*
-
Fentanyl / blood*
-
Fentanyl / pharmacokinetics*
-
Humans
-
Male
-
Mice
-
Models, Biological
-
Nitrite Reductases
-
Radioisotope Dilution Technique / standards
-
Radiopharmaceuticals / blood
-
Radiopharmaceuticals / pharmacokinetics
-
Receptors, Opioid, mu / metabolism*
-
Reference Standards
-
Tissue Distribution
-
Tomography, Emission-Computed / methods*
-
Tomography, Emission-Computed / standards*
Substances
-
Carbon Radioisotopes
-
Cytochromes
-
Radiopharmaceuticals
-
Receptors, Opioid, mu
-
Nitrite Reductases
-
nitrite reductase (NO-forming)
-
Electron Transport Complex IV
-
carfentanil
-
Fentanyl